Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3)

Diabetes Care

Volumn 37, Issue 8, 2014, Pages 2168-2176

  Umpierrez, Guillermo ^a   Povedano, Santiago Tofé ^b   Manghi, Federico Pérez ^c   Shurzinske, Linda ^d   Pechtner, Valeria ^d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Juaneda Clinic   (Spain)

^c Division of Cardiology   (Argentina)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DULAGLUTIDE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; ORAL ANTIDIABETIC AGENT; PLACEBO; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT;

ADULT; ARTICLE; BODY WEIGHT DISORDER; COMPARATIVE EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HEART RATE; HUMAN; HYPOGLYCEMIA; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PARALLEL DESIGN; PATIENT COUNSELING; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VOMITING; AGED; ANALOGS AND DERIVATIVES; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLUCAGON-LIKE PEPTIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN FC FRAGMENTS; MALE; METFORMIN; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 84904360390     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-2759     Document Type: Article

References (33)

1. DeFronzo RA, Okerson T, Viswanathan P., Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008; 24: 2943-2952
2. Elrick H, Stimmler L, Hlad CJ Jr, Arai Y. Plasma Insulin Response to Oral and Intravenous Glucose Administration. J Clin Endocrinol Metab 1964; 24: 1076-1082
3. Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 2011; 124 (Suppl.): S3-S18
4. Gedulin B, Jodka L, Hoyt J. Exendin-4 (AC2993) decreases glucagon secretion during hyperglycemia clamps in diabetic fatty Zucker rats (Abstract). Diabetes 1999; 48(Suppl. 1): A199
5. Jodka C, Gedulin BR, Young AA Exendin-4 potently regulates gastric emptying in rats. Diabetes 1998; 47(Suppl. 1): 1543
6. Gutzwiller JP, Drewe J, Göke B, et al. Glucagonlike peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999; 276: R1541-R1544
7. Turton MD, O'Shea D, Gunn I, et al A role for glucagon-likepeptide-1 inthe central regulation of feeding. Nature 1996; 379: 69-72
8. Glaesner W, Vick AM, Millican R, et al Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev 2010; 26: 287-296
9. Barrington P, Chien JY, Tibaldi F, Showalter H.D., Schneck K., Ellis B. LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects. Diabetes Obes Metab 2011; 13: 434-438
10. Grunberger G, Chang A, Garcia Soria G, Botros FT, Bsharat R, Milicevic Z. Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Diabet Med 2012; 29: 1260-1267
11. Umpierrez GE, Blevins T, Rosenstock J., Cheng C, Anderson JH, Bastyr EJ 3rd; EGO Study Group. The effects of LY2189265, a longacting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. Diabetes Obes Metab 2011; 13: 418-425
12. Sun F, Yu K, Yang Z., et al. Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysis. Exp Diabetes Res 2012; 2012: 230624
13. Inzucchi SE, Bergenstal RM, Buse J.B., et al.; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379
14. Garber AJ, Duncan TG, Goodman A.M., Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebocontrolled, dose-response trial. Am J Med 1997; 103: 491-497
15. World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997; 277: 925-926
16. Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005; 28: 1245-1249
17. Dmitrienko A, Tamhane AC Mixtures of multiple testing procedures for gatekeeping applications in clinical trials. Stat Med 2011; 30: 1473-1488
18. Westfall PHYS. Resampling-Based Multiple Testing: Examples and Methods for P-Value Adjustment. New York, Wiley, 1993
19. Williams-Herman D., Johnson J, Teng R., et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Curr Med Res Opin 2009; 25: 569-583
20. Goldstein BJ, Feinglos MN, Lunceford J.K., Johnson J., Williams-Herman DE; Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007; 30: 1979-1987
21. Jadzinsky M, Pfützner A, Paz-Pacheco E, Xu Z, Allen E., Chen R; CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009; 11: 611-622
22. Aschner P, Katzeff HL, Guo H, et al; Sitagliptin Study 049 Group. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab 2010; 12: 252-261
23. Chapell R, Gould AL, Alexander CM Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone. Diabetes Obes Metab 2009; 11: 1009-1016
24. Bloomgarden ZT, Dodis R, Viscoli C.M., Holmboe ES, Inzucchi SE. Lower baseline glycemia reduces apparent oral agent glucoselowering efficacy: a meta-regression analysis. Diabetes Care 2006; 29: 2137-2139
25. Garber A, Henry R, Ratner R., et al.; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473-481
26. Russell-Jones D., Cuddihy RM, Hanefeld M, et al; DURATION-4 Study Group. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 2012; 35: 252-258
27. Bailey CJ, Turner RC Metformin. N Engl J Med 1996; 334: 574-579
28. Montanya E, Sesti G. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Clin Ther 2009; 31: 2472-2488
29. Blevins T, Pullman J, Malloy J., et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011; 96: 1301-1310
30. DeVries JH, Bain SC, Rodbard H.W., et al.; Liraglutide-Detemir Study Group. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. Diabetes Care 2012; 35: 1446-1454
31. Diamant M, Van Gaal L, Stranks S, et al Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010; 375: 2234-2243
32. Nauck MA. A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks. Diabetes Care 2013; 36: 2126-2132
33. Robinson LE, Holt TA, Rees K, Randeva H.S., O'Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open 2013; 3: e001986